Share this article The immunology portfolio of AbbVie, which faced stiff competition from Humira biosimilars, saw revenues decrease by 9.6% to $26.14bn. Credit: Valery Zankovych
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes
With novel weight-loss drugs such as semaglutide (Wegovy) and tirzepatide (Zepbound) in short supply and selling for high prices, an age-old method for trying to